Scintimetric assessment of synovitis activity during treatment with disease modifying antirheumatic drugs

Potential Anti-SARS-CoV-2 Therapeutics That Target the Post-Entry Stages of the Viral Life Cycle: A Comprehensive Review

The coronavirus disease-2019 (COVID-19) pandemic continues to challenge health care systems around the world. Scientists and pharmaceutical companies have promptly responded by advancing potential therapeutics into clinical trials at an exponential rate. Initial encouraging results have been realized using remdesivir and dexamethasone. Yet, the research continues so as to identify better clinically relevant therapeutics that act either as prophylactics to prevent the infection or as treatments to limit the severity of COVID-19 and substantially decrease the mortality rate. Previously, we reviewed the potential therapeutics in clinical trials that block the early stage of the viral life cycle. In this review, we summarize potential anti-COVID-19 therapeutics that block/inhibit the post-entry stages of the viral life cycle. The review presents not only the chemical structures and mechanisms of the potential therapeutics under clinical investigation, i.e., listed in clinicaltrials.gov, but it also describes the relevant results of clinical trials. Their anti-inflammatory/immune-modulatory effects are also described. The reviewed therapeutics include small molecules, polypeptides, and monoclonal antibodies. At the molecular level, the therapeutics target viral proteins or processes that facilitate the post-entry stages of the viral infection. Frequent targets are the viral RNA-dependent RNA polymerase (RdRp) and the viral proteases such as papain-like protease (PLpro) and main protease (Mpro). Overall, we aim at presenting up-to-date details of anti-COVID-19 therapeutics so as to catalyze their potential effective use in fighting the pandemic.

Complications associated with use of levamisole-contaminated cocaine: an emerging public health challenge

Levamisole is an immunomodulatory agent that was used to treat various cancers before being withdrawn from the United States market in 2000 because of adverse effects. Levamisole is currently approved as an antihelminthic agent in veterinary medicine, but is also being used illicitly as a cocaine adulterant. Potential complications associated with use of levamisole-laced cocaine include neutropenia, agranulocytosis, arthralgias, retiform purpura, and skin necrosis. Treatment is primarily supportive, and skin lesions typically resolve with cessation of cocaine use. The incidence of hospitalizations related to use of levamisole-contaminated cocaine continues to increase and clinicians should be aware of the more common clinical manifestations.

Orthopaedic nuclear medicine: the pelvis and hip

Bone scintigraphy is a sensitive method useful in the diagnosis of specific skeletal problems encountered in orthopaedic and sports medicine. Often, in these situations, routine radiographic evaluation may provide negative or questionable information. Bone scintigraphy is also useful in the evaluation of patients with ill-defined or persistent bone pain not satisfactorily explained by positive radiologic evaluation. In these situations, because of its ability to image the whole body, bone scintigraphy may reveal additional unsuspected traumatic pathology, Finally, nuclear medicine physicians need to be prepared to properly interpret findings unrelated to trauma and to direct the evaluation of patients toward the correct diagnosis and subsequent management. These goals can be achieved by using optimal imaging technique, by becoming familiar with the patient's clinical presentation, by understanding the biomechanics and pathophysiology of the entities encountered, by proper use of alternative diagnostic procedures, and by establishing good rapport with referring physicians.